Cited by 723Neuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

The Role of Excitotoxicity in Neurodegenerative Disease

Doble, Adam·1999·Pharmacology & Therapeutics

Abstract

Glutamic acid is the principal excitatory neurotransmitter in the mammalian central nervous system. Glutamic acid binds to a variety of excitatory amino acid receptors, which are ligand-gated ion channels. It is activation of these receptors that leads to depolarisation and neuronal excitation. In normal synaptic functioning, activation of excitatory amino acid receptors is transitory. However, if, for any reason, receptor activation becomes excessive or prolonged, the target neurones become damaged and eventually die. This process of neuronal death is called excitotoxicity and appears to involve sustained elevations of intracellular calcium levels. Impairment of neuronal energy metabolism may sensitise neurones to excitotoxic cell death. The principle of excitotoxicity has been well-established experimentally, both in in vitro systems and in vivo, following administration of excitatory amino acids into the nervous system. A role for excitotoxicity in the aetiology or progression of several human neurodegenerative diseases has been proposed, which has stimulated much research recently. This has led to the hope that compounds that interfere with glutamatergic neurotransmission may be of clinical benefit in treating such diseases. However, except in the case of a few very rare conditions, direct evidence for a pathogenic role for excitotoxicity in neurological disease is missing. Much attention has been directed at obtaining evidence for a role for excitotoxicity in the neurolo…

Integrity signals

Registry

Crossref · 10.1016/s0163-7258(98)00042-4

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Doble, A.
Corresponding author
Doble, Adam
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
1999-03
Volume
81
Issue
3
Pages
163-221
ISSN
0163-7258 (ISSN-L)
OpenAlex
W111663151
Cited by
723
References
13
Citations by year
2026: 8 · 2025: 14 · 2024: 13 · 2023: 15 · 2022: 16 · 2021: 14 · 2020: 23 · 2019: 22 · 2018: 19 · 2017: 22 · 2016: 23 · 2015: 24 · 2014: 24 · 2013: 34 · 2012: 36
FWCI
3.28
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
excitotoxicity, neurodegenerative diseases, glutamate, glutamate receptors, intracellular calcium, neuronal energy metabolism, stroke, ischemic stroke, riluzole, amyotrophic lateral sclerosis, neurolathyrism, HIV-associated dementia, Parkinson's disease, Huntington's disease, mitochondrial dysfunction, neuroprotection
MeSH terms
Amyotrophic Lateral Sclerosis, Calcium, Humans, AIDS Dementia Complex, N-Methylaspartate, Neurotransmitter Agents, Glutamic Acid, Excitatory Amino Acids, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review